Table 3 Current and recent perioperative chemotherapy phase III trials for MIBC
Institution | Regimen | Setting | Status/Results | Trial ID |
|---|---|---|---|---|
University Hospital, Rouen | HD-MVAC vs. GC | Neoadjuvant or Adjuvant | Recruiting participants. | NCT01812369 |
Southwest Oncology Group | DD-MVAC vs. GC | Neoadjuvant | Recruiting participants [21]. | |
Japan Clinical Oncology Group | MVAC vs. Immediate RC | Neoadjuvant | Completed. 130 total subjects. OS increased by 35% in MVAC arm (64 subjects) but was not statistically significant. Improved pT0 rate with MVAC [22]. | |
FTRC | GC vs. Immediate RC | Adjuvant | Completed. 192 total subjects. No difference between adjuvant treatment (102) and control arms for 5 year OS. Failed to reach accrual goal, low study power [23]. | NCT00054626 |
Cairo University | GC + radiotherapy vs. radiotherapy alone | Adjuvant | Completed. 146 total subjects. Improvement in 45-month DFS from 28% to 70% in chemoradiotheraphy (72) group but failed to be statistically significant [24]. | NCT01734798 |
Eastern Cooperative Oncology Group | MVAC vs. PCa | Adjuvant | Completed. Results unreported. | NCT00003701 |
Sun Yat-Sen University | Intraarterial GC | Adjuvant | Recruiting Participants. | NCT01627197 |
Association of Urogenital Oncology | Adjuvant vs. Progression-Triggered Gemcitabine | Adjuvant | Completed. 114 total subjects. No statistically significant difference between adjuvant or progression-triggered Gemcitabine for DFS or OS. Failed to reach accrual goal [25]. | NCT00146276 |
EORTC | Adjuvant vs. Progression Triggered MVAC + Gemcitabine | Adjuvant | Closed early due to poor accrual | NCT00028756 |